Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 2/20 | 0.45 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.43 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.43 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | PRKCG | P05129 | 1/20 | 0.43 |
| ▸ | PRKCB | P05771 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | CDK4 | P11802 | 1/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29896410 | 1.00 | ALDH1A1 (0.50) | ALDH1A1NPSR1GAACNR2GRM4 | |
| SCHEMBL7308514 | 0.89 | GAA (0.51) | ALDH1A1NPSR1GAAAURKAPDGFRB | |
| SCHEMBL7306658 | 0.89 | PDPK1 (0.42) | ALDH1A1GAACNR2PDGFRBSIRT2 | |
| SCHEMBL7308745 | 0.89 | AR (0.41) | ALDH1A1GAAPDGFRBSIRT2SIRT1 | |
| SCHEMBL5773359 | 0.88 | HTT (0.53) | ALDH1A1NPSR1GAAKMT2AMAPT | |
| SCHEMBL12468985 | 0.87 | ALDH1A1 (0.46) | ALDH1A1NPSR1GAACNR2AURKA | |
| SCHEMBL1466285 | 0.86 | PDGFRB (0.51) | ALDH1A1NPSR1GAAAURKAPDGFRB | |
| SCHEMBL5778055 | 0.86 | ALDH1A1 (0.40) | ALDH1A1CNR2GRM4AURKAPDGFRB | |
| SCHEMBL7313954 | 0.86 | PSMB5 (0.41) | ALDH1A1GAACNR2AURKAPDGFRB | |
| Hydrochloric Acid SCHEMBL11046926 | 0.86 | TDO2 (0.43) | ALDH1A1GRM4PDGFRBSIRT2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1991006298-A1 | NEW USE OF CONDENSED QUINOLINE COMPOUND | KABI PHARMACIA THERAPEUTICS AB (SE) | 1991-05-16 | — | — | WO | claimed |
| US-4459298-A | PYRAZOLO/4,3-C/QUINOLIN-3-ONES | CIBA-GEIGY CORPORATION (US) | 1984-07-10 | — | — | US | claimed |
| US-4312870-A | TRANQUILIZERS, ANTIDEPRESSANTS | CIBA-GEIGY CORPORATION (US) | 1982-01-26 | — | — | US | claimed |
| EP-0022078-A1 | Pyrazolo-quinolines, processes for their production, and pharmaceutical compositions containing them | CIBA-GEIGY AG (CH) | 1981-01-07 | — | — | EP | claimed |
| EP-2164328-B1 | THERAPEUTIC PYRAZOLOQUINOLINE UREA DERIVATIVES | DART NEUROSCIENCE CAYMAN LTD (KY) | 2013-08-07 | — | — | EP | disclosed |
| EP-2164328-B1 | THERAPEUTIC PYRAZOLOQUINOLINE UREA DERIVATIVES | DART NEUROSCIENCE CAYMAN LTD (KY) | 2013-08-07 | — | — | EP | disclosed |
| US-8343957-B2 | Therapeutic pyrazoloquinoline urea derivatives | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2013-01-01 | — | — | US | disclosed |
| US-8343957-B2 | Therapeutic pyrazoloquinoline urea derivatives | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2013-01-01 | — | — | US | disclosed |
| US-8343957-B2 | Therapeutic pyrazoloquinoline urea derivatives | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2013-01-01 | — | — | US | disclosed |
| US-20110071140-A1 | THERAPEUTIC PYRAZOLOQUINOLINE UREA DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110071140-A1 | THERAPEUTIC PYRAZOLOQUINOLINE UREA DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110071140-A1 | THERAPEUTIC PYRAZOLOQUINOLINE UREA DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| WO-1991006298-A1 | NEW USE OF CONDENSED QUINOLINE COMPOUND | KABI PHARMACIA THERAPEUTICS AB (SE) | 1991-05-16 | — | — | WO | disclosed |
| EP-0182165-B1 | THIENYL CONDENSED-PYRAZOLE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 1989-08-16 | — | — | EP | disclosed |
| US-4758427-A | Enhanced absorption of psychoactive 2-aryl-pyrazolo quinolines as a solid molecular dispersion in polyvinylpyrrolidone | CIBA-GEIGY CORPORATION (US) | 1988-07-19 | — | — | US | disclosed |
| US-4751245-A | Antifungal derivatives of N-(6,6-dimethyl-2-hepten-4-ynyl)-1-naphthalenemethanamine and method of using same | E. R. SQUIBB & SONS, INC. (US) | 1988-06-14 | — | — | US | disclosed |
| EP-0214092-A1 | Enhanced absorption of psychoactive 2-aryl-pyrazolo quinolines as a solid molecular dispersion in polyvinylpyrrolidone | CIBA-GEIGY AG (CH) | 1987-03-11 | — | — | EP | disclosed |
| US-4459298-A | PYRAZOLO/4,3-C/QUINOLIN-3-ONES | CIBA-GEIGY CORPORATION (US) | 1984-07-10 | — | — | US | disclosed |
| US-4312870-A | TRANQUILIZERS, ANTIDEPRESSANTS | CIBA-GEIGY CORPORATION (US) | 1982-01-26 | — | — | US | disclosed |
| EP-0022078-A1 | Pyrazolo-quinolines, processes for their production, and pharmaceutical compositions containing them | CIBA-GEIGY AG (CH) | 1981-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071140-A1 | THERAPEUTIC PYRAZOLOQUINOLINE UREA DERIVATIVES | GABRB1, GABRA5, GABRB2 | ALDH1A1 447/4885NPSR1 99/4885GAA 2356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.